Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix Reports Q1 2020 Financial Results
WOBURN, Mass. , April 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2020 .  The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic
View HTML
Toggle Summary NeuroMetrix Reports Quell® Technology to be Used in NIH-Funded Trial Evaluating Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) for Fibromyalgia
WOBURN, Mass. , April 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology has been selected for use in a large, NIH -funded, randomized, pragmatic clinical trial of TENS for fibromyalgia.   Fibromyalgia is a disorder characterized by widespread
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for First Quarter 2020 Financial Results Conference Call
WOBURN, Mass. , April 16, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 first quarter financial results before the opening of the market on Thursday, April 23, 2020 . The Company will host a conference call at 8:00 a.m., Eastern Time on
View HTML
Toggle Summary NeuroMetrix Announces 2020 Annual Meeting of Shareholders Will Be Held in Virtual Meeting Format Only
WOBURN, Mass. , April 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that, due to the public health impact of the COVID-19 pandemic and in accordance with orders issued by the Governor of the Commonwealth of Massachusetts , the Company’s 2020 Annual Meeting of
View HTML
Toggle Summary NeuroMetrix Provides Quell® Technology Commercial Strategy and Pipeline Update
WOBURN, Mass. , March 11, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its Quell technology commercial strategy and pipeline. An estimated 100 million US adults have chronic pain. People with chronic pain may also have low quality sleep, anxiety, depression,
View HTML
Toggle Summary NeuroMetrix Reports Clinical Studies Recently Published on DPNCheck®
WOBURN, Mass. , March 05, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the recent publication of three additional DPNCheck clinical studies. DPNCheck is a point-of-care test that provides accurate and cost-effective screening, diagnosis and monitoring of peripheral
View HTML
Toggle Summary NeuroMetrix Reports Scientific Presentations at the American Academy of Pain Medicine 2020 Annual Meeting
WOBURN, Mass. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present two scientific posters at the American Academy of Pain Medicine (AAPM) 36 th Annual Meeting to be held February 26 - March 1 in National Harbor , MD.
View HTML
Toggle Summary NeuroMetrix Reports Q4 and Full Year 2019 Financial Results
WOBURN, Mass. , Jan. 27, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ) today reported financial and business highlights for the quarter and year ended December 31, 2019 . The Company develops and commercializes diagnostic and therapeutic neurostimulation-based medical devices.
View HTML
Toggle Summary NeuroMetrix, Inc. 2019 Financial Conference Call Rescheduled to Monday January 27, 2020
WOBURN, Mass. , Jan. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) today announced the shift of its 2019 financial conference call to Monday, January 27, 2020 at 8:00am Eastern Time . Internal scheduling conflicts caused the delay of two business days.
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2019 Financial Results Conference Call
WOBURN, Mass. , Jan. 17, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2019 fourth quarter and full year financial results before the opening of the market on Thursday, January 23, 2020 . The Company will host a conference call at 8:00 a.m.,
View HTML